Recent Updates
Recently added Catalysts
CORT Negative Sentiment Score: 25/100

Corcept Therapeutics Incorporated Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – CORT

Key Takeaway: Corcept Therapeutics has been named in a class action securities lawsuit due to alleged fraud involving false statements made regarding their drug relacorilant. The lawsuit, filed by Levi & Korsinsky, focuses on misleading claims made by the company about its interactions with the FDA and the anticipated approval of the drug, which may have misled investors. The time frame for the alleged fraudulent activity spans from October 31, 2024, to December 30, 2025. Affected investors have until April 21, 2026, to appoint a lead plaintiff in the case and may be eligible for compensation without incurring fees.

Market Sentiment Analysis

CONCERNS & RISKS

  • Corcept Therapeutics is facing a class action lawsuit for alleged securities fraud.
  • The lawsuit claims the company concealed information regarding the FDA's concerns about their drug relacorilant.
  • Defendants made materially false or misleading statements about the approval of relacorilant, impacting investor confidence.
  • Investors may suffer financial losses as a result of these allegations.

Full Press Release Details

NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated" or the "Company") (NASDAQ: CORT) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Corcept Therapeutics Incorporated investors who were adversely affected by alleged securities fraud between October 31, 2024 and December 30, 2025. Follow the link below to get more information and be contacted by a member of our team:
CORT investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: According to the filed complaint, defendants made false statements and/or concealed that: In light of the circumstances in which they were made, not false and misleading. In truth, the FDA had told Corcept that it had concerns about the adequacy of the program assessing relacorilant’s effectiveness in treating hypertension in patients with hypercortisolism, including the design of the GRACE study. The FDA had further told Corcept to expect significant issues with the review if Corcept was to submit the NDA. As a result, Defendants’ positive statements concerning their interactions with the FDA and their expectations that the relacorilant NDA would be approved, were materially false or misleading.
WHAT'S NEXT? If you suffered a loss in Corcept Therapeutics Incorporated during the relevant time frame, you have until April 21, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor

Tags

Frequently Asked Questions

What is the class action lawsuit about Corcept Therapeutics?

The lawsuit involves claims of securities fraud affecting investors between October 31, 2024, and December 30, 2025.

What is the deadline to join the Corcept lawsuit?

Investors have until April 21, 2026, to request appointment as lead plaintiff.

Do I need to pay to join the Corcept class action?

No, class members may receive compensation without any out-of-pocket costs.

How has Levi & Korsinsky performed in securities litigation?

Levi & Korsinsky has secured significant recoveries and ranks among the top firms in the U.S.

Who can I contact for more information on the lawsuit?

You can contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com.

Last updated: Apr 13, 2026